1、Summary Revenue Drivers R&D Progress Sustainability Financial Performance Financial Statements Glossary 1 29 July 2025 AstraZeneca results:H1 and Q2 2025 Strong growth momentum continues with excellent R&D pipeline delivery in the year-to-date Revenue and EPS summary H1 2025%Change Q2 2025%Change$m

2、Actual CER1$m Actual CER -Product Sales 26,670 8 10 13,795 11 10 -Alliance Revenue 1,293 38 38 654 36 35 Product Revenue2 27,963 9 11 14,449 12 11 Collaboration Revenue 82 68 66 8 2x 2x Total Revenue 28,045 9 11 14,457 12 11 Reported EPS($)3.46 31 32 1.58 27 31 Core3 EPS($)4.66 16 17 2.17 10 12 Key

3、performance elements for H1 2025(Growth numbers at constant exchange rates)Total Revenue up 11%to$28,045m,driven by double-digit growth in Oncology and BioPharmaceuticals Growth in Total Revenue across all major geographic regions Core Operating profit increased 13%Core EPS increased 17%to$4.66 12 p

4、ositive Phase III readouts and 19 approvals in major regions Interim dividend increased 3%to$1.03(76.7 pence,9.81 SEK)Pascal Soriot,Chief Executive Officer,AstraZeneca,said:“Our strong momentum in revenue growth continued through the first half of the year and the delivery from our broad and diverse

5、 pipeline has been excellent,with 12 positive key Phase III trial readouts including for baxdrostat,gefurulimab,and Tagrisso in just the past few weeks.As we enter our next phase of growth,we have pledged$50 billion to continue to grow in the US,which includes the largest manufacturing investment in

6、 AstraZenecas history,set for Virginia.This landmark investment reflects not only Americas importance but also our confidence in our innovative medicines to transform global health and power AstraZenecas ambition to deliver$80 billion revenue by 2030.”Guidance AstraZeneca reiterates its Total Revenu